PSTV (Cytori Therapeutics) Net earnings per share growth this year

PSTV (plustherapeutics.com) - company brandmark

How is Plus Therapeutics, Inc. (PSTV) combating brain cancer? Management is focusing on validating the efficacy of new radiotherapeutic methods. Year-over-year EPS growth reflects a trend where the parameter value equals 45.70. Stability is provided by a neutral US geopolitical backdrop and a network of specialized hubs for ultra-precise isotope delivery, which supports high business margins.

Earnings per share growth in current year: Cytori Therapeutics (PSTV) for 07/04/2022 - 08/03/2026

Analytical breakdowns and data insights for company Plus Therapeutics Inc (PSTV)

- stock quotes and analyst forecast:
Share Price Plus Therapeutics Inc|PSTV - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Plus Therapeutics|PSTV - Enterprise Value
- company book value details:
Net Asset Value per Share Plus Therapeutics|PSTV - Company Book Value|Market Value to Book Value plustherapeutics.com|PSTV - Aggregate Company Assets
- debt burden and liquidity indicators:
Aggregate Debt to Equity Plus Therapeutics, Inc.|PSTV - Long-Term Debt to Equity|Short-Term Debt to Equity Plus Therapeutics, Inc.|PSTV - Company Total Debt|Debts to Book Capitalization Plus Therapeutics, Inc.|PSTV - Company Long-Term Debt|Short-Term Debt Volume Plus Therapeutics|Intermediate Coverage Ratio plustherapeutics.com
- company profitability and valuation multiples indicators:
PSTV - Net Income|Future Net Profit Plus Therapeutics, Inc.|PSTV - P/E Multiple|Future Price to Earnings Multiple Plus Therapeutics Inc|PSTV - PEG Multiple|Company Value to EBITDA Plus Therapeutics, Inc.|PSTV - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Plus Therapeutics|PSTV - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth plustherapeutics.com|PSTV - Earnings per share growth in current year|Net earnings per share change forecast for next year Plus Therapeutics, Inc.
- revenue and sales proceeds data:
PSTV - Revenue and Sales Volume|Company Expected Sales Volume Plus Therapeutics, Inc.|PSTV - Market Cap to Revenue|Forward P/S Multiple Plus Therapeutics Inc
Summary company analysis:Plus Therapeutics, Inc.
Product sample of Plus Therapeutics

This indicator measures the year-over-year dynamics of earnings per share, reflecting the efficiency of capital generation. A stable upward trend in the annual EPS growth rate confirms the business's fundamental resilience to macroeconomic shocks. Investors should evaluate the rate of profit change as a marker of asset management quality. For Plus Therapeutics, Inc. (PSTV), this metric reflects the commercial success of implementing radiopharmaceuticals in neuro-oncology. The growth of this metric confirms the scaling of targeted isotope delivery technology within the nuclear medicine market.

Main competitors

Earnings per share growth this year OLMA|PBYI (pumabiotechnology.com) - Earnings growth in current year|Net earnings per share growth this year Greenwich LifeSciences (GLSI)|Earnings growth in current year ZNTL|MGNX - Earnings per share growth rate in current year|Earnings per share growth in current year Processa Pharmaceuticals PCSA|Earnings per share increase in current year EGRX